The verified answer
As of Aug 2026, DEPLOY verifies NeuroPace: 1 model. 1 source back the record.
CategoryBiometric wearables
Overview
NeuroPace (NASDAQ: NPCE) is a Mountain View-based medical device company that developed the RNS System, the only FDA-approved brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. Over 8,000 patients implanted. FY2025 revenue: 00M (25% YoY growth). 230+ Level 4 Comprehensive Epilepsy Centers in the US.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
Key facts
FDA
Product
Indication
Type
Data & sources
Web sources
1
1 source backing this record.View all →
Models (1)
View all models →NeuroPace on the deployment map
View the global mapNeuroPace has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for NeuroPace on the DEPLOY record yet. Track NeuroPace to know the moment the first one is verified.
Safety record
No incidents on record for NeuroPace.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
NeuroPace in third-party press
Financial state
- Reporting basis
- sec_10k
- Lifecycle stage
- growth
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdAug 8, 2026
Added to the verified registry
Sources (1)
Common questions
What is NeuroPace?
What does NeuroPace make?
Where is NeuroPace headquartered?
Where does NeuroPace operate robots?
Is NeuroPace a top robotics company?
Is NeuroPace safe?
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-08
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-08-08
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for NeuroPace.In the press
Recent coverage mentioning NeuroPace from third-party publications. Automatically surfaced; not part of the verified registry record.
Machine-readable surfaces
- Markdown mirror: /companies/neuropace.md
- RSS feed: /companies/neuropace/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/b553bad1-52b1-4096-b537-da7460d39812
- Revision history: /companies/neuropace/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Reality vs attention
NeuroPace draws attention at the 8th percentile but verifies reality at the insufficient-data level among biometric robots.
Analysis
Limited public visibility and press coverage relative to peers.
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Aug 9, 2026